

Vimta Labs Limited

Registered Office:

142, IDA Phase II, Cherlapally

Hyderabad-500 051 ,Telangana, India

T: +91 4027264141

F : +91 40 2726 3657

VLL\SE\050\2026-27**Date: 30.10.2026**

BSE Limited, P J Towers, Dalal Street, Mumbai: 400001. Scrip Code No.524394	National Stock Exchange of India Limited, “Exchange Plaza”, Bandra, Kurla Complex, Bandra (E),Mumbai – 400051. Trading Symbol: VIMTALABS
--	---

Dear Sir/Madam,

Sub: Investor Presentation –Q2 Results – FY 2026-27

Pursuant to provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “Listing Regulations”) we are enclosing herewith the Investor Presentation. Further, in terms of to Regulation 46 of the Listing Regulations, the aforesaid information will be available on the website of the Company i.e., <https://vimta.com/investors/investor-presentation/>

This is for your information and necessary records.

For VIMTA LABS LIMITED

SUJANI
VASIREDDI
Digitally signed by
SUJANI VASIREDDI
Date: 2026.10.30
13:22:41 +05'30'

Sujani Vasireddi**Company Secretary & Compliance Officer**

Plot No.5, Life Sciences Campus,Neovantage Science & Technology Park Private Limited , Shamirpet, Genome Valley,Turkapally,Medchal- Malkajgiri,
Hyderabad - 500 101, Telangana, India

T : +91 40 6740 4040 Email: mdoffice@vimta.com, Website URL : www.vimta.com

CIN : L24110TG1990PLC011977



Driven by Quality. Inspired by Science.

INVESTOR PRESENTATION

Q2 & H1 FY27 >



Disclaimer

The Presentation is to provide the general background information about the Company's activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.

This presentation may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global industries that we serve, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employees have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from Vimta Labs Ltd.



Table Of Contents

- Q2 & H1 FY27 Earnings
- Company Overview
- Industry Landscape
- Our Competitive Advantage
- Way Forward



Section 01

Q2 & H1 FY27 Earnings

- Q2 & H1 FY27 Highlights
- Key Metrics: Q2 & H1 FY27
- Profit & Loss Statement
- Financial Track Record
- Shareholding Pattern

Q2 FY27 Highlights

Rs 1,149 Mn

Total Income

Rs 408 Mn
Margin 35.5%

EBITDA

Rs 275 Mn

PBT

Rs 4.6

EPS

Rs 92 Mn
**CAPEX (Cash
Outflow)**

Rs 206 Mn
Margin 17.9%

PAT



H1 FY27 Highlights

Rs 2,278 Mn

Total Income

Rs 819 Mn
Margin 36.0%

EBITDA

Rs 559 Mn

PBT

Rs 9.3

EPS

Rs 701 Mn

**Cash & Cash
Equivalents***

Rs 417 Mn
Margin 18.3%


PAT

* Cash & Cash Equivalents include other bank balances




Key Metrics: Q2 FY27


Total Income (In ₹ Mn)




EBIDTA & EBIDTA Margin (In ₹ Mn, %)



PAT & PAT Margin (In ₹ Mn, %)




Basic EPS (In ₹)



Key Metrics: H1 FY27

Total Income (In ₹ Mn)


11.8%
YoY



EBIDTA & EBIDTA Margin (In ₹ Mn, %)

EBIDTA EBIDTA Margin


13.2%
YoY




PAT & PAT Margin (In ₹ Mn, %)

PAT PAT Margin

7.3%
YoY



Basic EPS (In ₹)




Profit & Loss Statement

Particulars (₹ Mn)	Q2 FY27	Q1 FY27	QoQ(%)	Q2 FY26	YoY (%)	H1 FY27	H1 FY26	YoY (%)
Revenue from Operations	1,120	1,091		1,018		2,211	1,994	
Other Income	29	38		27		67	44	
Total Income	1,149	1,129	1.8%	1,045	9.9%	2,278	2,038	11.8%
Material and Testing Costs	262	226		201		488	389	
Cost of lab setup	-	0		0		0	0	
Changes in inventories of work-in-progress	-	-		-		-	-	
Employee benefits expense	307	294		286		601	564	
Other expenses	173	197		189		370	361	
Total Expenses	741	718		676		1,459	1,315	
Exceptional Item	-	-		-		-	-	
EBIDTA	408	411	-0.8%	369	10.5%	819	723	13.2%
<i>EBIDTA (%)</i>	35.5%	36.4%		35.3%		36.0%	35.5%	
Finance costs	4	2		4		6	7	
Depreciation expense	129	125		102		254	201	
PBT	275	283	-2.9%	263	4.8%	559	515	8.4%
<i>PBT (%)</i>	24.0%	25.1%		25.1%		24.5%	25.3%	
Tax	69	73		64		142	127	
PAT	206	210	-2.0%	199	3.5%	417	388	7.3%
<i>PAT (%)</i>	17.9%	18.6%		19.1%		18.3%	19.0%	
Basic EPS (INR)	4.6	4.7	-2.1%	4.5	3.4%	9.3	8.7	7.0%





Financial Track Record

TOTAL INCOME (₹ Mn)




PROFITABILITY (₹ Mn)




BALANCE SHEET RATIOS


RoE (%)




RoCE (%)



Debt to Equity



Total Capex




1. Financial numbers for the period FY24 & FY25 are from continuing operations and exclude Diagnostic and Pathological services business

2. CAGR for the period FY20-FY26

Shareholding Pattern

Shareholding as on 30th September 2026



Share Information as on 30th September 2026

NSE Ticker	VIMTALABS
BSE Ticker	524394
Market Cap (INR Cr)	2,694.95
% free-float	64.36%
Free-float market cap (INR Cr)	1,734.42
Total Debt (INR Mn)	144.34
Cash & Cash Equivalents (INR Mn)**	701.12
Shares Outstanding	4,46,99,859
3M ADTV (Shares)*	4,05,173.04
3M ADTV (INR Cr)*	24.74
Industry	TIC

*Source: NSE & BSE

**Cash and Cash equivalents includes other bank balances





Section 02

Company Overview

- Vimta at a Glance
- Our Journey
- Our Offerings
- Geographical Presence
- Management

Vimta at a Glance

Established in **1984**, VIMTA is one of India's most renowned companies for contract research and testing, recognized for its high-quality, cutting-edge technology enabled wide spectrum, reliable services and vast experience. The company's broad capabilities span across biologics, small molecules, agro-chemicals, food & beverages, electronics, medical devices, home and personal care products, and environment testing.



42+ Years

Of experience in CRO industry



1,400+

Dedicated Multi-Disciplinary Team



~600,000

Sq. Ft. of Ultra-modern lab spaces



10

Labs and Offices across India



~100

Successful Regulatory Audits

Our Journey


	● Infrastructure	● People	● Investment	● Capabilities	● Revenues
2024	~600,000 ft ²	1300+	492 M	Pharma & Biopharma: Discovery & development services; Food; Environment; Electronics Testing	3,223 M
2015	400,000+ ft ²	1000+	580 M	Analytical – Pharma, Biopharma & Food; Clinical Research; Preclinical; Clinical Diagnostics; Environment Testing	1,073 M
2006	200,000+ ft ²	600+	992 M	Clinical Research; Environment; Analytical Testing – Food & Pharma	542 M
1992	50,000+ ft ²	150+	85 M	Environment; Analytical – Food & Pharma; Toxicology; Material testing; Clinical Research	16 M
1984	500 ft ²	6	200,000	Minerals & ores; Metals; Rice bran oil testing	156,000

1. Investment & Revenues in INR

2. Investments depicted may have spread across more than the denoted year



Our offerings



1. Drug discovery and development services

Offerings	Pharma Analytical	Clinical Research	Preclinical Research
Industry	Pharmaceuticals, Biologics, Nutraceuticals, Medical Devices, Animal Health		Pharmaceuticals, Biologics, Medical Device, Agrochemical, Speciality Chemicals
Accreditations & Regulatory Approvals	DCA, USFDA, WHO, EMA, DRAs of Ukraine, Turkey	CDSO, USFDA, WHO, MHRA, NPRA, and European DRAs	OECD-GLP, CCSEA, DSIR, AAALAC
Services	<p>Wide range of analytical services</p> <ul style="list-style-type: none"> E&L studies Stability testing Method development Validations Genotoxic impurities Elemental analysis In vitro studies Physical Characterisation Dissolution Testing Microbiology Immunogenicity studies Characterization Bioassays 		
		<ul style="list-style-type: none"> BA/BE Studies Bioanalytical Clinical Trials (Phase I to IV) Clinical End Point Studies Claim Studies 	<ul style="list-style-type: none"> Comprehensive in vitro, ex vivo and in vivo studies ADME, and PK IND enabling packages (genetic toxicology, safety pharmacology, general toxicology, & toxicokinetic studies). Chronic toxicology, reproductive toxicology, neurotoxicology, immunotoxicology, and carcinogenicity Biowaiver and alternative to animal studies Ecotoxicology, environmental fate and metabolism studies

2. Biologics - Contract Research & Development Services

Offerings	Process Development	Product Development
Industry	Biotech & Biopharma	
Requirements & guidelines	Small scale Non GMP (R&D)	ICH Guidelines (Q2, Q6B, etc.) Compliant
Services	<div>Process and Product Development – DS & DP</div> <div><div><ul style="list-style-type: none">○ Cell Line Development<ul style="list-style-type: none">• Cell line generation• Clone screening and selection• Cell bank preparation (MCB/WCB)• Expression optimization○ Upstream Process Development<ul style="list-style-type: none">• Media and feed optimization• Bioreactor process development• Scale-up studies• Process characterization</div><div><ul style="list-style-type: none">○ Downstream Process Development<ul style="list-style-type: none">• Protein purification development• Chromatography optimization• Yield and purity improvement○ Analytical Development<ul style="list-style-type: none">• Method development and validation• Protein characterization• Purity, potency, and stability testing• Glycosylation and aggregation analysis</div><div><ul style="list-style-type: none">○ Formulation Development<ul style="list-style-type: none">• Pre-formulation studies• Liquid and lyophilized formulations• Stability studies• Container-closure compatibility</div></div>	


3. Food, Agri & Environmental Testing

Industry	Food Manufacturing & Processing industries, Cultivation, Export, Retail, Nutraceuticals, Agro-chemicals, Water & Beverages, Animal Feed and post project monitoring services for various industries viz., Oil & Gas, Power, Cement, Mining, Infrastructure, etc.
No. of Locations	8 (Hyderabad, Mumbai (NFL), Ahmedabad, Bengaluru, Nellore, Nashik, Noida & Kolkata)
Accreditations & Regulatory Approvals	<ul style="list-style-type: none">• FSSAI, ISO 17025, BIS, APEDA, EIC, SHEFEXIL, EU Commission, OCED-GLP, AGMARK, Tea Board, Spices Board• Hyderabad Lab is a National Reference Lab for Water & Beverages Testing• Mumbai Lab is a National Food Laboratory, operated for FSSAI• MoEF, ISO 17025, QCI/NABET, OSHAS 45000 related to environmental testing services
Services	<ul style="list-style-type: none">• Food contaminants, food allergens, microbiology/pathogen, GMO testing, nutrition & composition analysis for all agri, food, food products, water and beverages• New product development support, validations and Shelf-life assessments• Packaging material testing• Nutraceuticals testing, method validations• Animal feed analysis• Agro-chemical (crop sciences): support for research and development, method development, validation and testing for regulatory submissions in India, Europe, South America, Japan, Southeast Asia• Post project monitoring• Industrial hygiene & Indoor air, SIA & hydrogeological studies• EHS audits, Hazardous waste study, Life cycle assessment and Due diligence studies• Green audit, Metrological studies

4. Electricals & Electronics Testing & Certification

Industry	Aviation, Defence, Medical Device, Telecom, Home appliances, Toys, Industrial & control equipment, Consumer electronics, Rail & Automotive, IT, IOT, physical security products, and allied industries
No. of Locations	2 (Hyderabad)
Accreditations & Regulatory Approvals	<ul style="list-style-type: none">• NABL ISO 17025, TEC• BIS & NABCB ISO 16025
Services	<ul style="list-style-type: none">• EMI/EMC testing• Radio Frequency testing• Environmental & reliability testing• Mechanical & electrical safety testing• Performance testing• Product Certification• CE marking

Geographical Presence



Pharma
Hyderabad



Food & Environment
Hyderabad
Ahmedabad
Noida
Mumbai (NFL)
Nashik
Bengaluru
Nellore
Kolkata



Electrical and Electronics
Hyderabad



Hyderabad (Headquarters) 



Pharma



Electronics & Electrical



Food & Environment

Key Management Team



S P Vasireddi
Executive Chairman

- Dr. S P Vasireddi is a Scientist – Technocrat – Entrepreneur having more than 45 years of experience in contract research and testing laboratory management. He is the founder and Chairman of VIMTA.
- Dr. Vasireddi is reckoned as the pioneer of CRO industry in India. He led VIMTA from a single bench laboratory to a wide spectrum, globally recognized CRTO. In recognition of his eminence in CRO & Testing industry he is/has been nominated as a member on the Advisory/ Governing Boards of several apex scientific and regulatory bodies of the country such as FSSAI, NABL etc.



Harita Vasireddi
Managing Director

- Harita has close to 3 decades years of experience in the TIC/CRO industry with track record of growth and profitability.
- Her Core competencies include management & driving organizational adaptability and development, quality management systems, and risk management.
- She holds an MBA in Operations Management from Boston College, USA; and is a B.Pharm graduate from Mysore university, India



Sreenivas Neerukonda
Executive Director

- Sreenivas's core competencies include strategic planning and execution, new service opportunities development, communication and relationship building, competitive intelligence, and fostering strong team relations to deliver goal-oriented performance.
- He holds an MBA in Management Information Systems, University of Oklahoma, USA; B.Pharm, Nagpur University, India.



Harriman Vungal
Executive Director - Operations

- Harriman was inducted to the Board as one of the Promoter Directors in 1990 and was appointed as Technical Director of the Company in 1992. He has extensive lab operations management experience and is a go to senior resource on GXPs.
- He has led the Company's effort in building state of the art IT infrastructure, systems and their compliance to applicable regulations.
- He holds D. Tech in Electronics from Toronto, Canada.



Siva Kambhampati
Chief Financial Officer

- Siva is a seasoned finance professional with a strong academic foundation. He is a CA and secured 63rd rank in cost accountancy. With over 17 years on experience in the engineering and pharmaceutical industries, he brings diverse expertise in strategic financial planning & management, product costing & pricing, and treasury management.
- He has previously worked at Artson Ltd. (A TATA Enterprise), Hyderabad as a CFO.




Section 03

Industry Landscape


- Market Opportunity
- Factors Driving Industry Growth

Markets Opportunity (Global)


Pharmaceutical Analytical Testing




Preclinical



Food Testing




Electronics Testing




Markets Opportunity (Indian)

Pharmaceutical Analytical Testing




2025 | 2035

Preclinical




2025 | 2033

Food Testing



2025 | 2033

Electronics Testing



2025 | 2035

Factors Driving Industry Growth





Section 04

Our Competitive Advantage

- Our Position in the CRTO Landscape
- Our Strength

Our Position in the CRTO Landscape

Pharma Analytical



- #1 in India
- Customers – 90% of India top 20
- 40% revenues from overseas

Clinical Research



- Among the most reputed CROs in India
- 75% of revenues from overseas

Electronics & Electricals



- One of the leading labs in Southern India

Food & Environment Testing



- Top 2 in India
- Serving 7 of India's top 10 food companies, large PSUs and Infra companies
- The only private EU commission approved lab in India

Preclinical



- Amongst Top 3 in India
- India's most comprehensive and integrated provider of non-clinical drug discovery and development services

Our Strengths





Section 05

Way Forward

- Our Key Growth Drivers & Strategies

Our Key Growth Drivers & Strategies

Favourable markets



- ✓ Growth momentum in markets
- ✓ Growing demand for safe & quality - drugs, food, electronics & clean environment

Core business strategies



- ✓ Capacity expansions
- ✓ Service innovations
- ✓ Penetration into new markets
- ✓ Customer partnerships

Core operational strategies



- ✓ Operational excellence
- ✓ Hiring right talent
- ✓ Quality & compliance culture
- ✓ Cutting edge technologies

Best practices



- ✓ Good corporate governance
- ✓ Risk management
- ✓ Listening to customers' needs
- ✓ Continuous learning



THANK YOU

Vimta Labs Ltd.

Siva Kambhampati | Chief Financial Officer
Siva.Kambhampati@vimta.com

Ernst & Young

Siddesh Chawan	Advait Bhadekar
Siddesh.Chawan@in.ey.com	Advait.Bhadekar@in.ey.com

Registered Office

#142, IDA Phase 2, Cherlapally,
Hyderabad Telangana, India. 500051

NSE: VIMTALABS

BSE: 524394

ISIN: INE579C01029

Website: www.vimta.com